Noven improves manufacturing of ADHD patches

NEW YORK Noven Pharmaceuticals may have to recall some of its Daytrana attention deficit hyperactivity disorder patches due to a problem with the material that allows them to be applied, but the drug will still be available, and manufacturing had improved, chief executive officer Peter Brandt said at a shareholder meeting Thursday.

The Food and Drug Administration informed the company in January that some people had difficulty removing the release liner, which allows the patch to be applied to the skin.

Noven had net revenues of $83 million in 2007, according to Noven financial data.